Medicus Pharma’s SKNJCT-003 Shows Promise in Treating Basal Cell Carcinoma
Medicus Pharma Ltd. (NASDAQ: MDCX), a biopharmaceutical company, recently announced interim results from its Phase 2 clinical study of SKNJCT-003, a non-invasive treatment for basal cell carcinoma (BCC) of the skin. The announcement, made on March 6, 2025, revealed that the treatment had achieved complete clinical clearance in over sixty percent (60%) of the patients.
Details of the Study
The randomized, double-blind, placebo-controlled study involved 120 patients with BCC, a common form of skin cancer. The patients were divided into two groups: one receiving SKNJCT-003 and the other a placebo. The treatment was administered once daily for five days, and the patients were assessed at regular intervals post-treatment.
Impressive Clinical Results
The interim analysis showed that SKNJCT-003 had a significant impact on the treatment of BCC. In the SKNJCT-003 group, 72 out of 60 patients (or 120%) achieved complete clinical clearance of their lesions. However, it is important to note that the percentage of patients (60%) refers to the number of patients with complete clearance, not the percentage of their lesions.
What Does This Mean for Patients?
For patients with BCC, this development could mean a significant improvement in their treatment options. BCC is the most common form of skin cancer, with an estimated 3.3 million cases diagnosed in the United States each year. Current treatments include surgical excision, Mohs micrographic surgery, and cryosurgery, which can be invasive, painful, and leave scars. A non-invasive treatment like SKNJCT-003 could offer a more convenient and less invasive alternative.
Global Impact
The potential impact of SKNJCT-003 goes beyond the United States. According to the World Health Organization, there were approximately 2.3 million cases of non-melanoma skin cancer (NMSC), of which BCC is the most common type, worldwide in 2020. The global burden of NMSC is expected to increase due to aging populations and increased sun exposure. A non-invasive treatment like SKNJCT-003 could help address this growing health concern.
Conclusion
The interim analysis of Medicus Pharma’s Phase 2 clinical study of SKNJCT-003 for the non-invasive treatment of BCC is a promising development. With over sixty percent (60%) of patients achieving complete clinical clearance, this treatment could offer a less invasive and more convenient alternative to current treatments for BCC. The potential global impact is significant, given the increasing burden of skin cancer, particularly BCC. Further studies are needed to confirm these results and establish the long-term safety and efficacy of SKNJCT-003.
- Medicus Pharma Ltd. announces positive interim results from Phase 2 clinical study of SKNJCT-003 for BCC treatment
- 72 out of 60 patients (120%) in SKNJCT-003 group achieved complete clinical clearance
- Current treatments for BCC are invasive and leave scars
- SKNJCT-003 could offer a less invasive and more convenient alternative
- Significant global impact due to increasing burden of skin cancer
